COVID-19: FDA’s Stenzel Talks Abbott Test, Future Clearances In Call
Executive Summary
Timothy Stenzel, director of the Office of In Vitro Diagnostics and Radiological Health within the US agency's device center, offered an update on a controversial Abbott test and covered other issues during a COVID-19 developer webinar.
You may also be interested in...
Abbott Sees Signs Of Post-Pandemic Recovery In Q2
Abbott’s medical device sales were down about 20% year-over-year in the second quarter of 2020, but diagnostics sales were up 7%. Procedure trends at the end of the second quarter suggest that demand for devices will soon recover to pre-pandemic levels.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Implant
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.